Published in
Ferrata Storti Foundation, Haematologica, p. haematol.2018.194399
DOI: 10.3324/haematol.2018.194399
Links
Tools
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Journal article published in 2018 by
Christian Winther Eskelund,
Alexandra Albertsson-Lindblad,
Arne Kolstad,
Anna Laurell,
Riikka Räty,
Lone Bredo Pedersen,
Christian Hartmann Geisler,
Mats Jerkeman,
Kirsten Grønbæk 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 